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Background: Contemporary randomized controlled trials (RCT) of coronary revascularization have not found any survival advantage from 
aggressive intervention, while observational data suggest otherwise. Our aim was to compare outcomes predicted from observational data without 
strict exclusion criteria with results from patients who would have been eligible for RCTs.
Methods: Based on Courage, ARTS, ERACI II and MASS II, we identified cotemporaneous Duke Cardiovascular Databank patients meeting RCT 
eligibility. We then used Cox proportional hazards models, stratified by treatment and adjusted for patient risk factors, to assess whether patients 
meeting trial criteria demonstrated different treatment-specific survival prognoses.
Results: Out of 8,798 Duke patients (overall mean age 62, 64% men, 53% mean ejection fraction, 63% hypertension, 29% diabetes mellitus, 52% 
cholesterol, 50% multi-vessel disease), a total of 2447 (28%), ranging from 3-15%, met RCT inclusion criteria. RCT eligible patients were significantly 
more likely to receive MED or CABG, be older, have higher blood pressure, higher ejection fraction, more 3-vessel disease and comorbidities, and 
lower GFR (p<0.0001) than those not eligible. Duke treatment assignment for Courage-eligible patients was 50:50 for medical therapy and PCI; but 
~75% of ARTS- and ERACI II-eligible Duke patients received bypass surgery and 25% had PCI. For MASS II-eligible patients, 46% received medical 
therapy, 30% PCI and 24% surgery. Unadjusted outcomes for eligible and ineligible patients were surprisingly similar. Inverse propensity weighted 
survivals comparing PCI and CABG suggest no significant differential treatment impact within trial-eligible and within non-eligible patients.
Conclusions: Our results show that RCT eligible patients represent a small percentage of patients in an observational dataset. Eligible 
patients have significantly different characteristics than ineligible patients but no significant differential survival. Applying RCT entry criteria to an 
observational dataset can help to determine reasons for discrepancies between RCT and observational data Results: 
